1,720,957 research outputs found
Pharmacological therapy for myocardial reperfusion injury
No full textIn the ischemic myocardium, reperfusion is necessary for the salvage of cells and cardiac function. However, reperfusion itself causes 'reperfusion injury', leading to the damage of myocardial cells. This is reduced by several interventions, as measured by the limitation of infarct size or reduction of arrhythmias. Pharmacological agents that protect against injury include Na+-H+ exchanger inhibitors, antioxidants, calcium antagonists, renin-angiotensin system antagonists and adenosine. N-acetylcysteine, diltiazem, verapamil, enalaprilat and adenosine have all showed promising results in patients with acute myocardial infarction when given before reperfusion. Cariporide was beneficial when added to cardioplegia. However, their use in daily practice awaits results from large clinical trials. © Elsevier Ltd. All rights reserved.Baran KW, 2001, CIRCULATION, V104, P2778, DOI 10.1161-hc4801.100236; Baxter GF, 2000, CARDIOVASC DRUG THER, V14, P607, DOI 10.1023-A:1007850527878; Belhomme D, 1999, CIRCULATION, V100, P340; Boyce SW, 2003, J THORAC CARDIOV SUR, V126, P420, DOI 10.1016-S0022-5223(03)00209-5; Bradamante S, 2003, EUR J PHARMACOL, V465, P115, DOI 10.1016-S0014-2999(03)01441-9; BUERKE M, 1995, CIRCULATION, V91, P393; Buerke M, 2001, J IMMUNOL, V167, P5375; Bull DA, 2003, ANN THORAC SURG, V75, pS735, DOI 10.1016-S0003-4975(02)04702-1; de Zwaan C, 2002, EUR HEART J, V23, P1670, DOI 10.1053-euhj.2002.3191; DREYER WJ, 1991, CIRCULATION, V84, P400; Faxon DP, 2002, J AM COLL CARDIOL, V40, P1199, DOI 10.1016-S0735-1097(02)02136-8; Fitch JCK, 1999, CIRCULATION, V100, P2499; Gao F, 2002, J PHARMACOL EXP THER, V301, P543, DOI 10.1124-jpet.301.2.543; Gonon AT, 2001, BASIC RES CARDIOL, V96, P454, DOI 10.1007-s003950170027; Gourine AV, 2001, AM J PHYSIOL-HEART C, V280, pH1105; Gumina RJ, 1998, J PHARMACOL EXP THER, V286, P175; HARTMAN JC, 1995, CARDIOVASC RES, V30, P47, DOI 10.1016-S0008-6363(95)00015-1; HARTMAN JC, 1993, J CARDIOVASC PHARM, V21, P996, DOI 10.1097-00005344-199306000-00022; Herzog WR, 1997, INT J CARDIOL, V59, P21, DOI 10.1016-S0167-5273(96)02883-5; Horstick G, 1997, CIRCULATION, V95, P701; Horwitz LD, 2001, J CARDIOVASC PHARM, V38, P859, DOI 10.1097-00005344-200112000-00007; Jalowy A, 1998, J AM COLL CARDIOL, V32, P1787, DOI 10.1016-S0735-1097(98)00441-0; JEFFREY S, 2003, AM HEART ASS SCI SES; Jones SP, 2004, AM J PHYSIOL-HEART C, V286, pH276, DOI 10.1152-ajpheart.00129.2003; Jordan JE, 2001, CIRCULATION, V104, P1413, DOI 10.1161-hc3601.095578; KAPLAN SH, 1995, CARDIOVASC RES, V29, P231, DOI 10.1016-S0008-6363(96)88575-0; KLEIN HH, 1995, CIRCULATION, V92, P912; Kobara M, 2003, J CARDIOVASC PHARM, V41, P880, DOI 10.1097-00005344-200306000-00008; Kroner A, 2002, EUR J CARDIO-THORAC, V21, P224, DOI 10.1016-S1010-7940(01)01110-1; Kurz T, 2001, AM J CARDIOL, V88, P1351, DOI 10.1016-S0002-9149(01)02112-9; Lazar HL, 2002, ANN THORAC SURG, V73, P1522, DOI 10.1016-S0003-4975(02)03461-6; LEFER DJ, 1993, CIRCULATION, V88, P1779; Linz W, 1999, CARDIOVASC RES, V43, P549, DOI 10.1016-S0008-6363(99)00091-7; Liu YH, 1996, HYPERTENSION, V27, P7; Maddock HL, 2002, AM J PHYSIOL-HEART C, V283, pH1307, DOI 10.1152-ajpheart.00851.2001; Marangelli V, 2000, Ital Heart J, V1, P336; Marzilli M, 2000, CIRCULATION, V101, P2154; MEHTA JL, 1990, J CARDIOVASC PHARM, V16, P112, DOI 10.1097-00005344-199007000-00016; Mentzer RM, 2003, ANN THORAC SURG, V75, pS700, DOI 10.1016-S0003-4975(02)04700-8; Miyoshi H, 2002, JPN J PHARMACOL, V89, P120, DOI 10.1254-jjp.89.120; Muraki S, 2001, J THORAC CARDIOV SUR, V121, P570, DOI 10.1067-mtc.2001.112342; Muraki S, 2003, J THORAC CARDIOV SUR, V125, P155, DOI 10.1067-mtc.2003.65; MUROHARA T, 1995, METHOD FIND EXP CLIN, V17, P499; Nicolau JC, 1996, AM J CARDIOL, V78, P1049, DOI 10.1016-S0002-9149(96)00535-8; OLAFSSON B, 1987, CIRCULATION, V76, P1135; ORIORDAN M, 2003, AM HEART ASS SCI SES; Pearl JM, 2001, ANN THORAC SURG, V72, P565, DOI 10.1016-S0003-4975(01)02782-5; Pernow J, 1997, CARDIOVASC RES, V33, P518, DOI 10.1016-S0008-6363(96)00265-9; Pizzetti G, 2001, Ital Heart J, V2, P757; Pruefer D, 2002, J THORAC CARDIOV SUR, V124, P942, DOI 10.1067-mtc.2002.123703; Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016-S0008-6363(02)00827-1; Rohmann S, 1995, CARDIOVASC RES, V30, P945, DOI 10.1016-S0008-6363(95)00154-9; Rupprecht HJ, 2000, CIRCULATION, V101, P2902; Rusnak JM, 2001, AM J CARDIOL, V88, P482, DOI 10.1016-S0002-9149(01)01723-4; SCHLACK W, 1993, J CARDIOVASC PHARM, V22, P89, DOI 10.1097-00005344-199307000-00015; Shimizu M, 1998, J CARDIOVASC PHARM, V32, P231, DOI 10.1097-00005344-199808000-00010; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; SMITH EF, 1993, EUR J PHARMACOL, V236, P477, DOI 10.1016-0014-2999(93)90487-3; Sochman J, 1996, CLIN CARDIOL, V19, P94; SOCHMAN J, 1990, INT J CARDIOL, V28, P191, DOI 10.1016-0167-5273(90)90060-I; Tadokoro H, 1996, J CARDIOVASC PHARM, V28, P134, DOI 10.1097-00005344-199607000-00020; Theroux P, 2000, CIRCULATION, V102, P3032; Theroux P, 1998, J AM COLL CARDIOL, V32, P620, DOI 10.1016-S0735-1097(98)00281-2; Wang QD, 2002, CARDIOVASC RES, V55, P25, DOI 10.1016-S0008-6363(02)00261-4; Weidenbach R, 2000, BRIT J PHARMACOL, V131, P138, DOI 10.1038-sj.bjp.0703544; WEYRICH AS, 1992, CIRCULATION, V86, P279; Wolfrum S, 2003, J CARDIOVASC PHARM, V41, P474, DOI 10.1097-00005344-200303000-00017; Zeymer U, 2001, J AM COLL CARDIOL, V38, P1644; Zhao ZQ, 2003, CARDIOVASC RES, V59, P132, DOI 10.1016-S0008-6363(03)003344-418211
Contrast-enhanced echocardiography for the diagnosis of apical hypertrophic cardiomyopathy
No full textThe echocardiographic diagnosis of apical hypertrophic cardiomyopathy can be difficult in patients with poor acoustic windows. However, contrast-enhanced echocardiography can provide better images in these patients and lead to the correct diagnosis. We present a patient with apical hypertrophic cardiomyopathy who was diagnosed using contrast-enhanced echocardiography. The use of contrast-enhanced echocardiography for the diagnosis of apical hypertrophic cardiomyopathy in patients with poor acoustic windows is discussed and the experience in the literature reviewed. © 2005 Blackwell Publishing.
Inflammation in atherosclerosis: A new therapeutic target
No full textCoronary artery disease (CAD) is still the leading cause of death in men and women, despite our better understanding of the disease process. Atherosclerosis, the underlying pathological process that leads to CAD, was considered a disorder of lipid metabolism and deposition of lipid material in the vessel wall. Today however, it is viewed as an inflammatory disease and it is evident that inflammation is involved in every step of plaque formation, progression and rupture. At the cellular level, recent studies on human and animal models illustrated the involvement of nuclear transcription factors in early lesion formation and lesion progression. Nuclear factor Kappa-B (NF-κB) activation can result in a proinflammatory, atherogenic process while peroxisome proliferator-activated receptors (PPARs) and their ligands have an atheroprotective, anti-inflammatory effect. Many drugs and compounds have been shown to block NF-κB or reduce its effects while others activate PPARs and slow or halt the inflammatory process. In this review, we will discuss the contribution of NF-κB and PPARs to the different inflammatory pathways that contribute to atherosclerosis. We will also discuss the effect on the inflammatory pathways by different therapeutic options like the angiotensin converting enzyme (ACE) inhibitors and the angiotensin receptor blockers (ARBs), insulin and insulin sensitizers, statins and fibrates, aspirin and salicylates, and antibacterial and antiviral therapy. © 2005 Bentham Science Publishers Ltd
A new device for easier handling of the transoesophageal echocardiography probe
No full text[No abstract available]0
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Get PDFWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
- …
